
| COVID-19 pneumonia, immunosuppression, and cytomegalovirus activation: A perspective #MMPMID33942769Ghosh KJ Postgrad Med 2021[Apr]; 67 (2): 65-66 PMID33942769show ga
?|*COVID-19/therapy[MESH]|*Cytomegalovirus Infections[MESH]|*Leukopenia[MESH]|COVID-19 Serotherapy[MESH]|Cytomegalovirus[MESH]|Humans[MESH]|Immunization, Passive[MESH]|Immunosuppression Therapy/adverse effects[MESH]
  
DeepDyve Pubget Overpricing | 
|